ThalesNano and Sanofi-Aventis collaborate on continuous process technologies

The collaboration will focus on the development and implementation of continuous process technologies from research to full-scale production. The purpose of the project is to study the utilization and application of ThalesNano’s integrated continuous process chemistry technologies within the Sanofi-Aventis drug R&D process from discovery to API production.

Ferenc Darvas, president and chairman of ThalesNano, said: “The benefits of continuous process chemistry over conventional batch chemistry includes the rapid synthesis of organic compounds, in particular under until now unrealizable hazardous reaction conditions.”